Fenofibrate inhibits reactive amyloidosis in mice.
OBJECTIVE
To examine the effects of the lipid-lowering agent fenofibrate on experimental AA amyloidosis and on serum amyloid A (SAA) levels.


METHODS
Fenofibrate was administered orally in a mouse model of amyloidosis, which is induced by injections of amyloid-enhancing factor and Freund's complete adjuvant. Fenofibrate was given for 3 weeks, including a 1-week course before induction of amyloidosis. Splenic amyloid deposits were evaluated histologically, and SAA levels were measured.


RESULTS
Fenofibrate inhibited the formation of splenic amyloid deposits and suppressed the elevation of SAA levels. CONCLUSION; Fenofibrate inhibits experimental amyloidosis by reducing levels of the precursor SAA.
Niigata University School of Medicine, Asahimachi 1-757, Niigata 951-8510, Japan.
Takehiro
T
Murai
Toshiyuki
T
Yamada
Takashi
T
Miida
Katsumitsu
K
Arai
Naoto
N
Endo
Tadamasa
T
Hanyu
D000209:Acute-Phase Proteins / Q000378:metabolism; D000686:Amyloidosis / Q000097:blood / Q000188:drug therapy*; D000818:Animals; D005260:Female; D011345:Fenofibrate / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D015850:Interleukin-6 / Q000097:blood; D051379:Mice; D008808:Mice, Inbred CBA; D000685:Serum Amyloid A Protein / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D000209:Acute-Phase Proteins; D000960:Hypolipidemic Agents; D015850:Interleukin-6; D000685:Serum Amyloid A Protein; D014280:Triglycerides; D011345:Fenofibrate